New Key Statistics Module, Z-Score and F-Score
XAMS:PHARM Key Ratios
Market Cap € M | 593.97 |
Enterprise Value € M | 555.12 |
P/E(ttm) | -- |
PE Ratio without NRI | -- |
Forward PE Ratio | -- |
Price/Book | 2.95 |
Price/Sales | 2.85 |
Price/Free Cash Flow | -- |
Price/Owner Earnings | -- |
Payout Ratio % | -- |
Revenue (TTM) € M | 227.00 |
EPS (TTM) € | -0.01 |
Beneish M-Score | -2.07 |
10-y EBITDA Growth Rate % | -- |
5-y EBITDA Growth Rate % | -19.10 |
y-y EBITDA Growth Rate % | -73.30 |
EV-to-EBIT | -98.06 |
EV-to-EBITDA | 61.29 |
PEG | -- |
Shares Outstanding M | 673.44 |
Net Margin (%) | -4.31 |
Operating Margin % | -9.06 |
Pre-tax Margin (%) | -4.93 |
Quick Ratio | 3.33 |
Current Ratio | 4.06 |
ROA % (ttm) | -2.42 |
ROE % (ttm) | -5.10 |
ROIC % (ttm) | -10.99 |
Dividend Yield % | -- |
Altman Z-Score | 1.90 |
XAMS:PHARM Number of Guru Trades
XAMS:PHARM Volume of Guru Trades
Gurus Latest Trades with XAMS:PHARM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
XAMS:PHARM is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Pharming Group Insider Transactions
No Available Data